New cell therapy methods for treating resistant melanoma
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
This study is looking for new ways to help patients with melanoma that hasn't improved with regular treatments by finding special markers in their tumors and using them to create targeted therapies that boost the immune system, and patients may have a chance to join trials testing these exciting new options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10932898 on NIH RePORTER |
What this research studies
This research focuses on developing innovative cell therapy approaches specifically for patients with melanoma that has not responded to standard treatments. It aims to identify unique antigens in melanoma tumors with specific mutations and create targeted therapies that can effectively engage the immune system. By utilizing T cell receptor-based immunotherapy, the project seeks to overcome the challenges posed by genetic mutations that hinder treatment effectiveness. Patients may have the opportunity to participate in trials that explore these new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma that has specific genetic mutations, particularly those resistant to current therapies.
Not a fit: Patients with melanoma that is not genetically defined or those who have not undergone prior treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with therapy-resistant melanoma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Klebanoff, Christopher Austin — Sloan-Kettering Inst Can Research
- Study coordinator: Klebanoff, Christopher Austin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.